Compare FRMI & BLCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FRMI | BLCO |
|---|---|---|
| Founded | 2025 | 1853 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Ophthalmic Goods |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.0B | 6.0B |
| IPO Year | N/A | 2022 |
| Metric | FRMI | BLCO |
|---|---|---|
| Price | $10.14 | $18.40 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 12 |
| Target Price | ★ $29.50 | $18.55 |
| AVG Volume (30 Days) | ★ 6.4M | 437.5K |
| Earning Date | 01-01-0001 | 05-21-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $5,101,000,000.00 |
| Revenue This Year | N/A | $7.45 |
| Revenue Next Year | $3,129.57 | $5.49 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 6.47 |
| 52 Week Low | $7.18 | $10.45 |
| 52 Week High | $32.39 | $18.92 |
| Indicator | FRMI | BLCO |
|---|---|---|
| Relative Strength Index (RSI) | 52.39 | 64.59 |
| Support Level | $8.69 | $16.35 |
| Resistance Level | $10.57 | N/A |
| Average True Range (ATR) | 1.03 | 0.63 |
| MACD | 0.18 | 0.11 |
| Stochastic Oscillator | 47.10 | 78.80 |
Fermi Inc is an energy and hyperscaler development company purpose-built for the AI era. Its Project Matador, a multi-gigawatt energy and data center development campus designed to support the accelerating needs of to-be-built AI infrastructure. Through its REIT structure, Fermi offers investors exposure to AI infrastructure growth and long-term, large-scale and reliable energy development in a tax-efficient public vehicle.
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.